SCHEMBL21133778

SCHEMBL21133778

Cc1cc2ccnc(C)c2cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.54
CCR1 P32246 4/20 0.38
CCR8 P51685 4/20 0.38
CCR5 P51681 3/20 0.38
PDE3B Q13370 3/20 0.37
PDE3A Q14432 3/20 0.37
UHRF1 Q96T88 1/20 0.34
KDM4E B2RXH2 3/20 0.34
NPC1 O15118 1/20 0.34
MAOA P21397 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NQO2 P16083 1/20 0.33
PRMT3 O60678 1/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CCNA1 P78396 1/20 0.33
CDK5 Q00535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27251652 0.81 CYP2A6 (0.44) CYP2A6CCR1CCR8CCR5PDE3B
SCHEMBL17278085 0.81 MAPT (0.45) CYP2A6PDE3BPDE3AKDM4EL3MBTL1
SCHEMBL20429172 0.78 CYP2A6 (0.36) CYP2A6CCR1CCR8CCR5UHRF1
SCHEMBL1521201 0.78 CYP2A6 (0.50) CYP2A6PDE3BPDE3AUHRF1KDM4E
SCHEMBL15427882 0.78 CYP3A4 (0.40) CYP2A6CCR1CCR8CCR5UHRF1
SCHEMBL8289930 0.78 ROCK1 (0.50) KDM4EMEN1KMT2AROCK1MAPT
SCHEMBL7514592 0.78 CYP2A6 (0.67) CYP2A6CCR1CCR8CCR5KDM4E
SCHEMBL26873044 0.77 CYP2A6 (0.64) CYP2A6CCR1CCR8KDM4ENPC1
SCHEMBL2757278 0.76 CYP2A6 (0.57) CYP2A6CCR1CCR8CCR5PDE3B
SCHEMBL8404535 0.76 CYP2A6 (0.57) CYP2A6CCR1CCR8CCR5UHRF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10344039-B2 Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use MERCK SHARP & DOHME CORP. (US) 2019-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344039-B2 Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use SERPINC1, PCSK9, KLKB1 CYP2A6 1080/4885CCR1 901/4885CCR8 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.